RVAC Medicines

The firm's business strategy centers on leveraging its mRNA technology to create treatments for infectious diseases, with a particular focus on emerging markets. Its pipeline includes vaccine candidates for COVID-19, Respiratory Syncytial Virus (RSV), and Clostridioides difficile (CDI). In September 2022, RVAC initiated its first-in-human clinical trial for a COVID-19 vaccine. The company’s revenue model is based on the development and future commercialization of these biopharmaceutical products. Strategic partnerships are a core component of its operating model, providing access to essential technologies and expertise. A key collaboration is with Acuitas Therapeutics for its proprietary lipid nanoparticle (LNP) delivery system, a critical component in some mRNA vaccines.

RVAC Medicines has secured significant financial backing to fuel its R&D and manufacturing expansion. In April 2022, the company completed a Series B financing round, raising its total funding to $140 million since its inception. This funding round was led by CBC Group with participation from investors including Pavilion Capital, EDBI, and GS Holdings. These funds are earmarked for the preclinical and clinical development of its pipeline, as well as for establishing new manufacturing facilities in Singapore and China. The company is also collaborating with organizations like the Coalition for Epidemic Preparedness Innovations (CEPI) to accelerate the manufacturing process for its next-generation mRNA vaccine platform, aiming to make vaccine production faster and more cost-effective.